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Abstract
Background: Somatostatin analogue-based radionuclide therapy with 177Lu-DOTATATE
is an important treatment option for patients with advanced neuroendocrine tumours
overexpressing somatostatin receptors. In addition to the kidneys, the bone marrow is
a major dose-limiting organ. The correlation between developed haematological toxicity
and absorbed dose to the bone marrow is poor, which indicates that other
factors affect haematological response. The spleen has an important role in the
haematopoetic system, including being a reservoir for blood cells. It is also the
organ that receives the highest mean absorbed dose during 177Lu-DOTATATE
treatment. The aim of this study was to analyse mean absorbed dose to the
spleen and its correlation with haematological toxicity, and to explore changes
in splenic volume.
The study included 41 patients treated with 7.2 GBq (3.5–8.3 GBq)
of 177Lu-DOTATATE on two to five occasions. Following each fraction, planar
whole-body scans were acquired at 2, 24, 48, and 168 h, and a SPECT/CT at
24 h post-injection. Mean absorbed spleen dose was calculated utilising planar
images for time-activity data and SPECT to adjust activity amounts. Splenic
volume information was collected from diagnostic CT scans at baseline and
follow-up.
Results: Median and total absorbed spleen doses were estimated to 4.5 and
15 Gy, respectively. Total absorbed spleen dose correlated with decrease in Hb
(p = 0.02), but not WBC (p = 0.31) or PLT (p = 0.65) counts. For patients without
bone metastases, mean absorbed spleen dose correlated with decrease in PLT
(p = 0.04) but not Hb (p = 0.16) or WBC (p = 0.42) counts. The spleen volume was
reduced to 75 % (p < 0.001) of original values (200 vs. 260 ml) at a mean follow-
up of 36 months.
Conclusions: Haematological toxicity according to Hb counts was moderately
but significantly correlated with total absorbed spleen dose. This supports the
possibility that radiation exposure of the spleen affects overall haematological
response during 177Lu-DOTATATE treatment.
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Background
Somatostatin analogue-based PRRT using 177Lu-DOTATATE for patients with ad-
vanced neuroendocrine tumours that overexpress somatostatin receptors has become
an established treatment option included in published guidelines [1]. A majority of
treated patients are reported to have clinically relevant effects in terms of symptom re-
lief, improved quality of life, and radiological response [2–4]. The dose-limiting organs
for all PRRT are mainly the kidneys and the bone marrow [2, 3]. Mean absorbed dose
to the kidneys is routinely calculated at each fraction, and treatment is usually ended at
a fixed absorbed dose to avoid the risk of serious renal complications, as a possible
dose-response relationship between kidney dose and renal function has been described
[5, 6]. However, clinically relevant renal toxicity is very seldom reported in 177Lu-based
PRRT [2, 7].
Haematological toxicity, used as an indirect measure of bone marrow exposure, more
often occurs during treatment, and serious cytopenia (grade 3 or 4 according to the
National Cancer Institute’s Common Terminology Criteria for Adverse Events, version
3.0) has been described in 10 % of patients in larger reports [2, 8]. However, individual
bone marrow dosimetry is only occasionally performed during 177Lu-DOTATATE
treatment, both because of the lack of a clear dose-response relationship and the
assumption that the dose to the bone marrow will not exceed the used dose limit
of 2 Gy [2, 9, 10]. The poor correlation between mean absorbed dose to the bone
marrow and developed haematological toxicity in published studies [9, 10] is prob-
ably due to the fact that several factors influence haematological response. Earlier
studies on haematological toxicity during 177Lu-DOTATATE treatment have re-
vealed associations with renal function, tumour burden [11, 12], initial cytopenia
[8, 11], previous chemotherapy, and patient age [11].
An additional factor that may affect the development of haematological toxicity is ra-
diation exposure of the spleen. In a long-term follow-up study of 203 patients receiving
177Lu-DOTATATE, 16 patients with earlier splenectomy developed less haematological
toxicity [8]. The spleen is part of the immune system; it has the ability to produce
blood cells and acts as a reservoir for red and white blood cells and platelets [13–15].
Furthermore, it is often reported to be the organ that receives the highest mean
absorbed dose during PRRT [3, 16]. The reason for the radiation exposure is physio-
logical uptake of somatostatin in the splenic tissue [17, 18]. Immunohistochemical
studies combined with measurement of mRNA reveal a predominance of somatostatin
receptor subtype 2A in the spleen [19]. This receptor subtype is preferred by both the
somatostatin analogues most often used to diagnose and treat neuroendocrine tumours:
octreotide and octreotate.
Prior knowledge about radiation exposure of the spleen was obtained from studies of
external radiotherapy, where the spleen is irradiated to relieve pain due to splenic en-
largement from malignant disease. Side effects from this treatment are described in
terms of a decline in haemoglobin (Hb), white blood cell (WBC), and platelet (PLT)
counts, which may be due to direct exposure of the blood cells that are physiologically
pooled in the spleen, or to a response from haematopoetic cells situated in the spleen
[20–24]. Radiation response was also demonstrated in these studies by a desired reduc-
tion in the volume of the spleen; as a result of this, effective pain relief is achieved. The
aim of this study was to examine the possible role of the spleen in the development of
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haematological toxicity during 177Lu-DOTATATE treatment. Changes in splenic vol-
ume at follow-up were also explored.
Methods
Patients and treatment characteristics
This study included 41 patients with advanced neuroendocrine tumours. The study was
approved by the Regional Ethics Review Board in Gothenburg, Sweden, and performed
in accordance with the principles of the Declaration of Helsinki and national regula-
tions. The need for written informed consent was waived. Patients included in the
study had tumours judged to overexpress somatostatin receptors (i.e., uptake exceeding
physiological liver uptake) by somatostatin receptor scintigraphy (111In-DTPA-octreotide,
Octreoscan®; Mallinckrodt). All patients had clinically, biochemically, or radiologically
confirmed progressive disease and a renal 51Cr-EDTA clearance >40 mL/min/1.73 m2.
Each fraction was administered as a 30-min infusion of 7.2 ± 1.3 GBq (3.5–8.3 GBq) of
177Lu-DOTATATE coinfused with kidney-protecting amino acids (2.5 % lysine and 2.5 %
arginine in 1 L of 0.9 % NaCl, infusion rate 250 mL/h) to a total amount of 24 ± 7.1 GBq
(8.2–40 GBq) on two to five occasions, 6–8 weeks apart.
Dosimetry
For dosimetry of at-risk organs, including the spleen, planar images were acquired at 2,
24, 48, and 168 h post-injection (p.i.), and single photon emission computed tomog-
raphy (SPECT)/CT was performed at 24 h p.i. To calculate the mean absorbed dose to
the spleen, a hybrid technique was used, that utilised information from both planar and
SPECT images. The spleen was identified, and a region of interest (ROI) was drawn on
the planar images. For background subtraction, a small ROI below the spleen was
drawn. The activity in the ROI was calculated for the different time points according to
the conjugate view method, as described in a previous study [12]. For this calculation,
the thickness of the spleen and the thickness of the body over the spleen were acquired
from the 24-h SPECT/CT. A volume of interest (VOI) around the spleen was also
drawn from the 24-h SPECT; the activity amount in the VOI was then calculated and
the activity concentration decided. A factor of 0.85 was used to correct for the partial
volume effect, which was determined from SPECT simulation studies using the re-
search image platform PhONSAi, developed in-house [25]. The accuracy of the SPECT
simulation of the partial volume effect was verified against measurement of the partial
volume effect in the NEMA phantom, and a high agreement was found. The acquired
activity concentration from the SPECT was applied to adjust the planar time-activity
curves, and the accumulated activity within the spleen was calculated from the area






where Ã is the adjusted accumulated activity in the spleen, Δ is the energy emitted by
the radionuclide per disintegration (147 keV for 177Lu, [26]), φ is the absorbed fraction
of energy from the β-particles, which was assumed to be one, and M is the mass of the
spleen with a supposed density of unity. The mean absorbed dose was estimated by
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assuming local absorption of the β-particles emitted from 177Lu and neglecting the
minor contribution from photons (≤2 %; [27, 28]).
Diagnostic CT scans were used to estimate splenic volumes before treatment and in
long-term follow-up by manual ROI drawing in all CT slices in the image platform
PhONSAi. All diagnostic CT scans used for spleen volume estimates were contrast-
enhanced, slice thickness 5 mm.
Bone marrow dosimetry was not performed in this study. This is subject of a separate
work by our research group, including development of a novel image-based method for
bone marrow dose estimates.
Assessment of haematological response
Patients were monitored according to bone marrow function (Hb, WBC, and PLT
counts) by blood sampling every 2 weeks during the treatment period. Blood samples
were analysed according to standard procedures at the hospital. For an estimation of
the decline in Hb, WBC, and PLT counts, the nadir value after treatment start was
compared to baseline, and this relative value was related to the mean absorbed dose to
the spleen per treatment and to the total mean absorbed dose.
Statistical methods
Associations between a decrease in blood counts from baseline values and the mean
absorbed dose to the spleen were investigated by analysis of variance (ANOVA) in linear
regression analysis. Residuals of the linear regression analysis (Hb and PLT values) were
found to be normally distributed according to the Anderson-Darling test. Means and
standard deviation are used to report normally distributed continuous variables, otherwise
median values and range are reported. p values <0.05 were considered significant.
Results
As illustrated in Fig. 1, the uptake of 177Lu-DOTATATE by the spleen was often higher
than uptake by other organs, which resulted in a relatively high mean absorbed spleen
dose per treatment for the 41 patients included in the study. Median absorbed dose was
estimated to 4.7 Gy (1.5–10.6 Gy) per 7.4 GBq of 177Lu-DOTATATE (Fig. 2). For all treat-
ments, the median absorbed spleen dose was estimated to 15 Gy (5.8–39 Gy) from an
average activity amount of 24 ± 7.1 GBq (8.2–37 GBq). A moderate correlation was seen
between total absorbed dose to the spleen and decrease in Hb (p = 0.02; Fig. 3) but not
WBC (p = 0.31) or PLT (p = 0.65) counts. For patients without bone metastases (n = 26)
the correlation with Hb counts was not significant (p = 0.06; Fig. 3). Mean absorbed dose
to the spleen per treatment seemed associated with a decrease in PLT counts, although
not significantly (p = 0.06). For patients without bone metastases, it reached significance
(p = 0.04; Fig. 3). No statistically significant correlation was obtained between mean
absorbed bone marrow dose and Hb (p = 0.16) or WBC (p = 0.42) counts.
A general decline in splenic volume was observed after 177Lu-DOTATATE treatment.
Mean volume of the spleen (n = 31) was 260 mL (54–640 mL) before treatment start,
compared to 200 mL (41–600 mL) after a mean follow-up of 36 months from the first
fraction given, which represents a decrease to 75 % (40–131 %) of the original volume
(p < 0.001). Figure 4 shows an example of a patient who experienced a volume reduc-
tion of the spleen to 40 % of the original value after three treatments of 177Lu-
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DOTATATE and a total absorbed spleen dose of 13 Gy. The magnitude of volume re-
duction was not correlated to mean absorbed spleen dose per treatment (p = 0.53) or
total absorbed dose for all treatments (p = 0.20).
Discussion
This study found a modest correlation between total absorbed dose to the spleen and
Hb counts in blood (p = 0.02). The mean absorbed dose to the spleen seemed
Fig. 1 SPECT/CT (acquired 24 h p.i.) of 177Lu-DOTATATE illustrating the relatively high physiological uptake
of 177Lu-DOTATATE in the spleen (S) and kidneys (K), resulting in high absorbed doses. This patient, a
woman with an ileal NET, received a mean absorbed dose of 6.4 Gy to the spleen and 3.1 Gy to the
kidneys from this treatment. The colour bar indicates the uptake intensity. Multiple tumours with a
pathological uptake are present in the liver (L)
Fig. 2 Mean absorbed doses to the spleen per 7.4 GBq of 177Lu-DOTATATE for the different fractions. The
grey dotted line indicates the median absorbed dose per 7.4 GBq for all 41 patients (4.7 Gy; coefficient of
variation = 0.19). No. number
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associated to the decrease in PLT counts though not significantly (p = 0.06). This correl-
ation reached significance for patients with no bone metastases (p = 0.04). The reason
for these differences may be that patients with bone metastases are a more heteroge-
neous group including those with one or two bone metastases as well as patients with
massive engagement and prerequisites of substantial bone marrow infiltration. The po-
tential influence of the spleen on haematological response was noted also by Sabet et
al. [8]. They reported a significantly lower degree of haematological toxicity (according
to NCI CTCAE) for patients receiving 177Lu-DOTATATE, who had previously under-
gone splenectomy (16 out of 203 patients). This suggests that these patients’ blood
cells were protected from being irradiated in the blood reservoir situated in the
spleen. However, another published study that included 53 patients treated with
177Lu-DOTATATE did not find a correlation between absorbed dose to the spleen
Fig. 3 Correlations between total absorbed spleen dose and relative decline in Hb count during
177Lu-DOTATATE treatment, for all patients (a) and for patients without bone metastases (b), and
correlations between mean absorbed spleen dose per treatment and PLT count, for all patients
(c) and for patients without bone metastases (d)
Fig. 4 Patient with an ileal NET that metastasised to abdominal lymph nodes. The patient received three
fractions of 177Lu-DOTATATE to a total amount of 22 GBq. Splenic volume at baseline was 415 cm3 (left). At
follow-up 5 years after treatment start, splenic volume was 167 cm3 (right), a volume reduction of 60 %.
Total absorbed dose to the spleen was estimated to 13 Gy
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and haematological toxicity. This may be due to the fact that the evaluation in this
study was made after only one fraction, and a reported mean absorbed dose to the
spleen of 6.3 Gy, which could be too small an exposure for a detectable haemato-
logical response [29].
A correlation between irradiation of the spleen and the development of cytopenia
was reported for external radiotherapy used to reduce splenic volume in patients with
haematological disorders, at fraction doses of 0.2–1 Gy/fraction to a total mean
absorbed dose of 2–10 Gy [20, 21]. The low absorbed doses required for a haemato-
logical response in patients undergoing external radiotherapy may reflect the fact that
patients with haematological disorders have other predisposing factors. For example,
these patients are likely to have active haematopoesis in the spleen [30], which means
that haematopoetic stem cells will be irradiated, while patients in the present study
have mainly mature blood cells pooled in the spleen, with different radiosensitivity. In
addition, the absorbed dose rate will be considerably higher from external radiotherapy
than from 177Lu-based radionuclide therapy. The absorbed dose rates in these studies
varied between 0.2 and 1 Gy per fraction, supposedly delivered in minutes, while radio-
nuclide therapy from a low/medium-energy β-emitter such as 177Lu would be expected
to yield an absorbed dose rate of <0.02 Gy/h [31, 32].
Hb counts were correlated with the total mean absorbed dose to the spleen (p = 0.02)
but not with the mean absorbed dose per treatment. This might reflect a relatively
lower radiosensitivity of red blood cells compared to PLTs, as well as a slower regener-
ation. The regeneration time for red blood cells is estimated to 120 days, compared to
10 days for platelets [13, 33]. The WBC count did not seem to differ with absorbed
spleen dose in this study, which could be due to the fact that WBCs are not pooled in
the spleen to the same extent and they have a faster regeneration time [33].
The present study clearly demonstrate that the spleen responds to radiation exposure
from 177Lu-DOTATATE with a reduction in volume, similar to that observed with ex-
ternal radiotherapy [21, 22], despite differences in fractionation, total doses, and splenic
function between these two patient groups. Whether the spleen is affected physiologic-
ally by the radiation exposure remains to be investigated.
Although a dose-dependent relationship may exist between the mean absorbed dose
to the spleen and the blood cell count, there are several other factors that contribute to
the haematological response during 177Lu-DOTATATE treatment. Recently, associa-
tions were observed between haematological toxicity and renal function [11, 12], initial
cytopenia [8], tumour burden [11, 12], and patient age [11]. The fact that several bio-
logical parameters influence the haematological response may explain why strong cor-
relations with absorbed bone marrow dose are difficult to find. Further analysis to
capture the spleen impact on haematological response in relation to other biological
parameters will be subject of an upcoming multivariate and compartment analysis by
the research group.
Conclusions
Haematological toxicity according to haemoglobin counts was moderately but significantly
correlated with accumulated mean absorbed dose to the spleen during 177Lu-DOTATATE
treatment. This supports the possibility that also radiation exposure of the spleen affects
overall haematological response during this therapy, which illustrates its complexity.
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